The where, when, and how of community-based versus clinic-based ART delivery in South Africa and Uganda

TY - JOUR

T1 - The where, when, and how of community-based versus clinic-based ART delivery in South Africa and Uganda

AU - Nachega, Jean B.

AU - Fatti, Geoffrey

AU - Zumla, Alimuddin

AU - Geng, Elvin H.

N1 - Funding Information: JBN is an infectious diseases internist and epidemiologist supported by the US National Institutes of Health (NIH)/National Institutes of Allergy and Infectious Diseases (grant number 5U01AI069521; Stellenbosch University Clinical Trial Unit of the AIDS Clinical Trial Group) as well as NIH/Fogarty International Center (grant numbers 1R25TW011217-01; African Association for Health Professions Education and Research) and 1D43TW010937-01A1 (University of Pittsburgh HIV Comorbidities Research Training Programme in South Africa), and is co-principal investigator of TOGETHER, an adaptive randomised clinical trial of novel agents for treatment of patients who are high-risk outpatients with COVID-19 in South Africa supported by the Bill & Melinda Gates Foundation. AZ is a co-principal investigator of the Pan-African Network on Emerging and Re-Emerging Infections funded by the European and Developing Countries Clinical Trials Partnership and is in receipt of an NIH Research Senior Investigator award. We acknowledge the critical review by John Johnson (Case Western Reserve University, Cleveland, OH, USA). We declare no competing interests.

PY - 2020/10

Y1 - 2020/10

UR - https://www.scopus.com/pages/publications/85091242682

U2 - 10.1016/S2214-109X(20)30385-5

DO - 10.1016/S2214-109X(20)30385-5

M3 - Comment/debate

C2 - 32971045

AN - SCOPUS:85091242682

SN - 2572-116X

VL - 8

SP - e1245-e1246

JO - The Lancet Global Health

JF - The Lancet Global Health

IS - 10

ER -